Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy

Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy

ABSTRACT Aim Combination immunotherapy is the standard of care for advanced hepatocellular carcinoma (HCC). However, some patients are unsuitable for such treatment. This study investigated the safety and effectiveness of durvalumab monotherapy in a real‐world cohort with advanced HCC who were poor...

Full description

Saved in:
Bibliographic Details
Main Authors: Chihiro Miwa, Sadahisa Ogasawara, Takuya Yonemoto, Sae Yumita, Tomomi Okubo, Miyuki Nakagawa, Keisuke Koroki, Masanori Inoue, Naoya Kanogawa, Masato Nakamura, Takayuki Kondo, Shingo Nakamoto, Norio Itokawa, Masanori Atsukawa, Ei Itobayashi, Naoya Kato
Format: Article
Language:English
Published: Wiley 2025-03-01
Series:Cancer Medicine
Subjects:
Child–Pugh B
chronic kidney disease
durvalumab
hepatocellular carcinoma
immunotherapy
real‐world study
Online Access:https://doi.org/10.1002/cam4.70642
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70642

Similar Items